India's Pharma Export Gap: How Indian Generic and API Manufacturers Can Close Russia's $9 Billion Import Shortfall

Russia’s $9 billion generics and Active Pharmaceutical Ingredient (API) import bill remains largely uncaptured by Indian manufacturers. The widest gaps sit in cardiovascular generics, oncology APIs, anti-infectives and high-volume solid oral dosage forms. This mismatch matters now because supplier withdrawals since 2022, tighter European trade routes and Russia’s localisation policy have narrowed established sourcing channels. Indian pharma exporters already possess the manufacturing scale, dossier capability and cost base to compete, yet exports to Russia reached only $577 million in FY2025. 

Where Russia’s Pharma Import Shortfall Is Widest

Russia continues to rely on foreign supply across the pharmaceutical value chain, including APIs, excipients, finished dosage forms, packaging components and production technologies. The strongest opportunities sit in established therapeutic categories with high prescription volumes and recurring procurement demand. Cardiovascular medicines, oncology products, diabetes therapies, anti-infectives and central nervous system drugs remain commercially relevant. Solid oral dosage forms also align with India’s established strength in large-scale generic manufacturing. p/

India exported $20.5 billion in formulations and biologicals during FY2023–24, showing the scale available to serve larger markets. For Indian generic manufacturers, Russia presents a different test from regulated Western markets: product selection must match local tenders, reimbursement patterns and distributor demand. API suppliers serving Russia and CIS buyers also need to show reliable lead times, impurity control and batch-to-batch consistency. Price opens discussions, but dependable supply protects the contract. 

EAEU Pharmaceutical Registration Sets The Entry Standard

Market access starts with Eurasian Economic Union registration, supported by a Common Technical Document dossier and evidence that the manufacturing site meets EAEU Good Manufacturing Practice (GMP). Applicants select a reference member state, then pursue recognition in other member states. Dossier assessment, deficiency responses, site inspection and national administrative steps can extend entry beyond twelve months. Planning should begin before commercial negotiations reach final terms.

Labels and patient information must be provided in Russian, reflect approved product particulars and comply with serialisation requirements. Packaging changes may trigger dossier updates. Foreign manufacturing sites should prepare inspection records, validation files, stability data and deviation histories for review. Payment arrangements require equal attention. Rupee–rouble settlement routes exist, but currency conversion, bank acceptance and repatriation terms vary. Contracts should define the settlement currency, price-adjustment triggers, Incoterms and responsibility for customs documentation. 

Why Indian Pharma Exporters Have A Commercial Window In Russia

India’s pharma exports to Russia totalled $577 million in FY2025, a small share of India’s global pharmaceutical sales. That gap signals limited market penetration rather than limited capability. Russian buyers are widening supplier searches as traditional channels become less predictable. At the same time, local manufacturers need APIs, excipients, contract development and manufacturing organisation (CDMO) capacity, processing equipment and packaging inputs to support domestic output.

The commercial case rests on disciplined portfolio selection. Manufacturers should favour molecules with recurring demand, manageable registration risk and production economics that remain viable after distributor margins, logistics and currency movement. Firms that can reduce line stoppages, protect yield and maintain consistent release performance will carry more weight than suppliers competing on unit price alone. The current window rewards reliable operating evidence, not broad claims about capacity.

What Indian Manufacturers Need To Compete In Eurasia

A credible Indian pharma market-entry plan for Eurasia requires four connected workstreams: regulatory readiness, local representation, supply design and buyer development. Regulatory teams need gap assessments against EAEU GMP, complete analytical methods and submission-ready stability packages. Commercial teams need distributors with tender access, pharmacovigilance capability and a strong record in the target therapeutic category. 

Supply plans should account for route options, safety stock, customs clearance and cold-chain controls where relevant. Documentation must remain consistent across the dossier, batch records, certificates of analysis and shipping files. ISO systems may support operational control, but market access depends on pharmaceutical regulation and verified GMP practice. Trade platforms can shorten partner discovery by bringing manufacturers, CDMOs, ingredient suppliers, distributors and procurement leads into one setting, allowing technical and commercial checks to progress together. 

Meet Russian And CIS Pharma Buyers At Pharmtech And Ingredients 

Indian generic and API manufacturers, CDMOs and ingredient suppliers seeking regional buyers can meet decision-makers at Pharmtech and Ingredients. The exhibition connects pharmaceutical production suppliers with buyers who influence sourcing, investment, and technical procurement decisions across Russia and the CIS. 

Submit an exhibitor enquiry to start qualified conversations with Russian and CIS buyers.